-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FCdviagPm8dnN3TDhxyzopk+fX8lJf9k4vm/2rOzcueXfTZIXaEXtfMDSqj2GXSf 1Wl+EjRGhx1ET2WEw+xoMA== 0000929638-09-001421.txt : 20090916 0000929638-09-001421.hdr.sgml : 20090916 20090916184734 ACCESSION NUMBER: 0000929638-09-001421 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090914 FILED AS OF DATE: 20090916 DATE AS OF CHANGE: 20090916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: El-Hibri Fuad CENTRAL INDEX KEY: 0001380185 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 091073224 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (301) 795-1800 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 form4_ex.xml X0303 4 2009-09-14 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 2273 RESEARCH BLVD, SUITE 400 ROCKVILLE MD 20850 1 1 1 0 CEO & Chairman Common Stock 2009-09-14 4 M 0 37700 3.50 A 975119 D Common Stock 2009-09-14 4 S 0 37700 19.26 D 937419 D Common Stock 2009-09-15 4 M 0 16270 3.50 A 953689 D Common Stock 2009-09-15 4 M 0 54000 10.13 A 1007689 D Common Stock 2009-09-15 4 M 0 3730 7.00 A 1011419 D Common Stock 2009-09-15 4 S 0 74000 19.67 D 937419 D Common Stock 2009-09-16 4 M 0 29604 7.00 A 967023 D Common Stock 2009-09-16 4 S 0 50000 19.84 D 917023 D Common Stock 5011 I By Karim El-Hibri Trust Common Stock 5011 I By Yusra El-Hibri Trust Common Stock 5011 I By Faiza El-Hibri Trust Common Stock 7181835 I By Intervac, L.L.C. Common Stock 2965043 I By BioPharm, L.L.C. Common Stock 1599155 I By Biovac, L.L.C. Employee Stock Option (right to buy) 3.50 2009-09-14 4 M 0 37700 0 D 2008-01-01 2010-05-25 Common Stock 37700 102582 D Employee Stock Option (right to buy) 3.50 2009-09-15 4 M 0 16270 0 D 2008-01-01 2010-05-25 Common Stock 16270 86312 D Employee Stock Option (right to buy) 10.13 2009-09-15 4 M 0 54000 0 D 2013-12-12 Common Stock 54000 27000 D Employee Stock Option (right to buy) 7.00 2009-09-15 4 M 0 3730 0 D 2015-03-10 Common Stock 3730 96270 D Employee Stock Option (right to buy) 7.00 2009-09-16 4 M 0 29604 0 D 2015-03-10 Common Stock 29604 66666 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2009, as modified on August 11, 2009. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $19.09 to $19.36. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $19.40 to $19.85. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $19.80 to $19.91. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Mr. El-Hibri holds, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Intervac, L.L.C. is the direct owner of 7,181,835 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein in 2,731,079 shares. Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 2,965,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,191,057 shares. Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares. The option vests in three equal installments on December 12, 2007, December 12, 2008 and December 12, 2009. The option vests in three equal installments on March 11, 2009, March 11, 2010 and March 11, 2011. /s/ Carl A. Valenstein, attorney-in-fact 2009-09-16 -----END PRIVACY-ENHANCED MESSAGE-----